125 related articles for article (PubMed ID: 27352182)
21. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases.
Etoh T; Inoue H; Tanaka S; Barnard GF; Kitano S; Mori M
Cancer Res; 2001 Mar; 61(5):2145-53. PubMed ID: 11280779
[TBL] [Abstract][Full Text] [Related]
22. Identification of calreticulin as a prognosis marker and angiogenic regulator in human gastric cancer.
Chen CN; Chang CC; Su TE; Hsu WM; Jeng YM; Ho MC; Hsieh FJ; Lee PH; Kuo ML; Lee H; Chang KJ
Ann Surg Oncol; 2009 Feb; 16(2):524-33. PubMed ID: 19050968
[TBL] [Abstract][Full Text] [Related]
23. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
Shiomi H; Eguchi Y; Tani T; Kodama M; Hattori T
Am J Pathol; 2000 Feb; 156(2):567-75. PubMed ID: 10666386
[TBL] [Abstract][Full Text] [Related]
24. E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma.
Yonemura Y; Nojima N; Kaji M; Fujimura T; Itoh H; Ninomiya I; Miyazaki I; Endo Y; Sasaki T
Cancer; 1995 Sep; 76(6):941-53. PubMed ID: 8625219
[TBL] [Abstract][Full Text] [Related]
25. High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer.
Vidal O; Metges JP; Elizalde I; Valentíni M; Volant A; Molina R; Castells A; Pera M
Br J Surg; 2009 Dec; 96(12):1443-51. PubMed ID: 19918848
[TBL] [Abstract][Full Text] [Related]
26. [Expression of transcription factor SP1, vascular endothelial growth factor and CD34 in serosa-infiltrating gastric cancer and their relationship with biological behavior and prognosis].
Wei YZ; Li CF; Xue YW
Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Mar; 12(2):145-9. PubMed ID: 19296249
[TBL] [Abstract][Full Text] [Related]
27. [Relationship between the expression of vascular endothelial growth factor, fms-like tyrosine kinase-1 and biological behavior in gastric carcinoma].
Wang YY; Ye ZY; Zhao ZS; Tao HQ
Zhonghua Wei Chang Wai Ke Za Zhi; 2007 May; 10(3):269-73. PubMed ID: 17633783
[TBL] [Abstract][Full Text] [Related]
28. Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues.
Umeda T; Eguchi Y; Okino K; Kodama M; Hattori T
J Pathol; 1997 Dec; 183(4):388-97. PubMed ID: 9496254
[TBL] [Abstract][Full Text] [Related]
29. Pathobiological significance of vascular endothelial growth factor and Maspin expressions in human gastric carcinoma.
Li JJ; Chen Y; Zhang SM; Wu DY; Wang YP; Xin Y
World J Gastroenterol; 2004 Sep; 10(18):2624-7. PubMed ID: 15309707
[TBL] [Abstract][Full Text] [Related]
30. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients.
Lieto E; Ferraraccio F; Orditura M; Castellano P; Mura AL; Pinto M; Zamboli A; De Vita F; Galizia G
Ann Surg Oncol; 2008 Jan; 15(1):69-79. PubMed ID: 17896140
[TBL] [Abstract][Full Text] [Related]
31. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma.
De Petro G; Tavian D; Copeta A; Portolani N; Giulini SM; Barlati S
Cancer Res; 1998 May; 58(10):2234-9. PubMed ID: 9605771
[TBL] [Abstract][Full Text] [Related]
32. Markers of progression and invasion in short term follow up of untreated breast cancer patients.
Rabi ZA; Todorović-Raković N; Vujasinović T; Milovanović J; Nikolić-Vukosavljević D
Cancer Biomark; 2015; 15(6):745-54. PubMed ID: 26406416
[TBL] [Abstract][Full Text] [Related]
33. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
[TBL] [Abstract][Full Text] [Related]
34. [Expression of vascular endothelial growth factors (VEGF)-A, -C and -D and their prognostic significance and relationship with angio- and lymphangiogenesis in gastric cancer].
Wang XL; Ai ZS; Fang JP; Tang RY; Chen XM
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):837-43. PubMed ID: 19173829
[TBL] [Abstract][Full Text] [Related]
35. Correlation of vascular endothelial growth factor expression with tumor recurrence and poor prognosis in patients with pN0 gastric cancer.
Liu YF; Guo S; Zhao R; Chen YG; Wang XQ; Xu KS
World J Surg; 2012 Jan; 36(1):109-17. PubMed ID: 21773953
[TBL] [Abstract][Full Text] [Related]
36. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
37. [Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients].
Xiao W; Tong WL; Ma DD
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Nov; 29(11):723-6. PubMed ID: 17327049
[TBL] [Abstract][Full Text] [Related]
38. Vascular endothelial growth factor and endoglin (CD-105) in gastric cancer.
Nikiteas NI; Tzanakis N; Theodoropoulos G; Atsaves V; Christoni Z; Karakitsos P; Lazaris AC; Papachristodoulou A; Klonaris C; Gazouli M
Gastric Cancer; 2007; 10(1):12-7. PubMed ID: 17334712
[TBL] [Abstract][Full Text] [Related]
39. Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining.
Takai S; Yamamura M; Tanaka K; Kawanishi H; Tsuji M; Nakane Y; Hioki K; Yamamoto M
Int J Cancer; 1991 Apr; 48(1):20-7. PubMed ID: 1902201
[TBL] [Abstract][Full Text] [Related]
40. Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer.
Lee KH; Bae SH; Lee JL; Hyun MS; Kim SH; Song SK; Kim HS
Oncology; 2004; 66(3):210-7. PubMed ID: 15218312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
